<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NITROPRUSSIDE SODIUM</span><br/>(nye-troe-pruss'ide)<br/><span class="topboxtradename">Nipride, </span><span class="topboxtradename">Nitropress<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antihypertensive</span>; <span class="classification">nonnitrate vasodilator</span><br/><b>Prototype: </b>Hydralazine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Potent, rapid-acting hypotensive agent with effects similar to those of nitrates.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts directly on vascular smooth muscle to produce peripheral vasodilation, with consequent marked lowering of arterial BP,
         associated with slight increase in heart rate, mild decrease in cardiac output, and moderate lowering of peripheral vascular
         resistance.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term, rapid reduction of BP in hypertensive crises and for producing controlled hypotension during anesthesia to reduce
         bleeding.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Refractory CHF or acute MI.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Compensatory hypertension, as in atriovenous shunt or coarctation of aorta, and for control of hypotension in patients with
         inadequate cerebral circulation. Safety during pregnancy (category C) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic insufficiency, hypothyroidism, severe renal impairment, hyponatremia, older adult patients with low vitamin B<sub>12</sub> plasma levels or with Leber's optic atrophy.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertensive Crisis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.510 mcg/kg/min (average 3 mcg/kg/min)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Solutions must be freshly prepared with D5W and used no later than 4 h after reconstitution.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Continuous:</span> Dissolve each 50 mg in 23 mL of D5W. Further dilute in 250 mL D5W to yield 200 mcg/mL or 500 mL D5W to yield 100 mcg/mL.
                  Following reconstitution, solutions usually have faint brownish tint; if solution is highly colored, do not use it. Promptly
                  wrap container with aluminum foil or other opaque material to protect drug from light.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Continuous:</span> Administer by infusion pump or similar device that will allow precise measurement of flow rate required to lower BP. Give
                  at the rate required to lower BP but do not exceed the maximum dose of 10 mcg/kg/min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Amiodarone,</b>
<b>dobutamine,</b>
<b>propafenone.</b>
<span class="incompattype">Y-site:</span>
<b>Cisatracurium,</b>
<b>haloperidol.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solutions protected from light; stable for 24 h.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Diaphoresis, apprehension, restlessness, muscle twitching, retrosternal discomfort. <span class="speceff-life">Thiocyanate toxicity</span> (profound hypotension, tinnitus, blurred vision, fatigue, metabolic acidosis, pink skin color, absence of reflexes, faint
      heart sounds, loss of consciousness). <span class="typehead">CV:</span> Profound hypotension, palpitation, increase or transient lowering of pulse rate, bradycardia, tachycardia, ECG changes. <span class="typehead">GI:</span> Nausea, retching, abdominal pain. <span class="typehead">Metabolic:</span> Increase in serum creatinine, fall or rise in total plasma cobalamins. <span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">Special Senses:</span> Nasal stuffiness. <span class="typehead">Other:</span> Irritation at infusion site. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> Within 2 min. <span class="typehead">Duration:</span> 110 min after infusion is terminated. <span class="typehead">Metabolism:</span> Rapidly converted to cyanogen in erythrocytes and tissue, which is metabolized to thiocyanate in liver. <span class="typehead">Elimination:</span> Excreted in urine primarily as thiocyanate. <span class="typehead">Half-Life:</span> (thiocyanate): 2.77 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor constantly to titrate IV infusion rate to BP response.</li>
<li>Relieve adverse effects by slowing IV rate or by stopping drug; minimize them by keeping patient supine.</li>
<li>Notify physician immediately if BP begins to rise after drug infusion rate is decreased or infusion is discontinued.</li>
<li>Monitor I&amp;O.</li>
<li>Lab tests: Monitor blood thiocyanate level in patients receiving prolonged treatment or in patients with severe kidney dysfunction
            (levels usually are not allowed to exceed 10 mg/dL). Determine plasma cyanogen level following 1 or 2 d of therapy in patients
            with impaired liver function.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>